Partnering to champion policies that drive the discovery, development and delivery of transformative medicines and vaccines.
New medicines and vaccines save lives and help make our healthcare system more cost‑effective.
Preventing or curing disease means extending lives, relieving suffering and improving people’s quality of life.
Promoting a robust regulatory protocol means ensuring safe and effective medicines for Canadians.
Supporting sustainable healthcare means we all spend more time enjoying life and being productive.
Innovative Medicines Canada members
High-quality jobs
Yearly economic impact
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
Press Release December 05, 2022
Ottawa, ON – Innovative Medicines Canada (IMC) has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised […]
Press Release November 22, 2022
Ottawa, ON – Innovative Medicines Canada (IMC) is once again disappointed by the inaccurate and misleading information on the value […]
Featured News November 15, 2022
Ottawa, ON – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that Dr. Allison McGeer […]
Press Release November 10, 2022
Ottawa, ON – Innovative Medicines Canada (IMC) is calling on Health Canada to direct the Patented Medicine Prices Review Board […]
Press Release November 08, 2022
OTTAWA, ON – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that Dr. Megan MacPherson […]
Press Release October 18, 2022
Ottawa, October 18, 2022 – Innovative Medicines Canada’s (IMC) initial interpretation of the Patented Medicine Prices Review Board’s (PMPRB) revised […]
Press Release August 24, 2022
Ottawa, August 24, 2022 – Today, the Health Research Foundation (HRF) of Innovative Medicines Canada (IMC) launched the call for […]
Press Release July 06, 2022
Ottawa, July 6, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, acknowledges the amendments to […]
Informative content to keep you up to date on the most pressing issues facing our industry.
